Cargando…
Development of a mechanistic model to predict synthetic biotic activity in healthy volunteers and patients with phenylketonuria
The development of therapeutics depends on predictions of clinical activity from pre-clinical data. We have previously described SYNB1618, an engineered bacterial therapeutic (synthetic biotic) for the treatment of Phenylketonuria (PKU), a rare genetic disease that leads to accumulation of plasma ph...
Autores principales: | Charbonneau, Mark R., Denney, William S., Horvath, Nicholas G., Cantarella, Pasquale, Castillo, Mary J., Puurunen, Marja K., Brennan, Aoife M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298439/ https://www.ncbi.nlm.nih.gov/pubmed/34294862 http://dx.doi.org/10.1038/s42003-021-02183-1 |
Ejemplares similares
-
Development of synthetic biotics as treatment for human diseases
por: Brennan, Aoife M
Publicado: (2022) -
Variability and Lability of Ammonia Levels in Healthy Volunteers and Patients With Cirrhosis: Implications for Trial Design and Clinical Practice
por: Bajaj, Jasmohan S., et al.
Publicado: (2019) -
Complications of the Low Phenylalanine Diet for Patients with Phenylketonuria and the Benefits of Increased Natural Protein
por: McWhorter, Nicole, et al.
Publicado: (2022) -
Nitrogen Balance after the Administration of a Prolonged-Release Protein Substitute for Phenylketonuria as a Single Dose in Healthy Volunteers
por: Scheinin, Mika, et al.
Publicado: (2021) -
Improvement of a synthetic live bacterial therapeutic for phenylketonuria with biosensor-enabled enzyme engineering
por: Adolfsen, Kristin J., et al.
Publicado: (2021)